Teva Pharmaceutical Industries Limited American Depositary Shares (TEVA)
18.19
+0.35 (1.96%)
Teva Pharmaceutical Industries is a global leader in the pharmaceutical industry, specializing in the development, production, and marketing of a wide range of generic and specialty medications
The company is committed to improving patient access to high-quality medicines and focuses on therapeutic areas such as central nervous system disorders, pain management, respiratory diseases, and more. With a robust portfolio that includes both branded and generic products, Teva leverages its extensive research capabilities to innovate and provide solutions that meet the evolving healthcare needs of patients and healthcare professionals around the world.
Teva reported fourth-quarter revenue of $4.2 billion, beating analyst estimates of $4.13 billion, according to Benzinga Pro. The company reported fourth-quarter adjusted earnings of 71 cents per share, beating estimates of 70 cents per share.
FDA issues new warnings about rare but severe allergic reactions, including anaphylaxis, linked to MS drug glatiramer acetate, urging immediate medical attention.
HHS adds 15 drugs to Medicare Part D price negotiations, targeting cost reductions under the Inflation Reduction Act. New prices aim to save billions by 2027.
Catalyst Pharmaceuticals settles patent litigation with Teva, delaying generic Firdapse launch until 2035. Legal actions against other defendants remain ongoing.
Novo Nordisk petitions the FDA to exclude liraglutide from the 503B Bulks List, citing safety risks, lack of clinical need, and the availability of approved alternatives.
